Events Search and Views Navigation

Event Views Navigation

Filters

Changing any of the form inputs will cause the list of events to refresh with the filtered results.

Current

Relmada Therapeutics Virtual KOL Event to Discuss Topline Phase 2 Data for NDV-01 for High-Grade Non-Muscle Invasive Bladder Cancer (HG-NMIBC) at AUA 2025

Join Relmada Therapeutics for a virtual key opinion leader (KOL) event featuring Boris Chertin, MD (Department of Urology, Shaare Zedek…
TIME: 4:30 PM EDT
LOCATION: Virtual
View Details

Foghorn Therapeutics Virtual Investor Event to Review Key Pipelines Updates in Conjunction with 2025 AACR Meeting

Join Foghorn Therapeutics for a virtual investor event to review updates for FHD-909, a potential first-in-class selective SMARCA2 inhibitor, including…
TIME: 8:00 AM EDT
LOCATION: Virtual
View Details

Praxis Precision Medicines virtual investor event to discuss clinical programs in Developmental and Epileptic Encephalopathies (DEEs)

Join Praxis Precision Medicines for a virtual investor event hosted by company management, who will focus on their DEE clinical…
TIME: 10:00 AM EDT
LOCATION: Virtual
View Details

BioVersys AG Virtual KOL Event: BV100 Shows Survival Benefit in Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter. What Does that Mean for Patients? A Perspective from the US and from Asia.

Join BioVersys for a virtual key opinion leader (KOL) event featuring Professor David Paterson (ADVANCE-ID, Saw Swee Hock School of…
TIME: 8:30 AM EDT
LOCATION: Virtual
View Details

Eupraxia Pharmaceuticals Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE)

Join Eupraxia Pharmaceuticals for a virtual KOL event featuring key opinion leader (KOL) Evan Dellon, MD, MPH (University of North Carolina,…
TIME: 9:00 AM EDT
LOCATION: Virtual
View Details

Atea Pharmaceuticals Virtual KOL Event to Discuss the Current Challenges for Patients with Hepatitis C, Results from Atea’s Phase 2 Study of the regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients

Join Atea Pharmaceuticals for a virtual panel discussion featuring several key opinion leaders (KOLs) including: Eric Lawitz, MD - Texas Liver…
TIME: 10:00 AM EDT
LOCATION: Virtual
View Details

Inmagene Biopharmaceuticals Virtual KOL Event to Discuss the Potential Role of Anti-OX40/OX40L Monoclonal Antibodies (mAbs) in the Treatment of Alopecia Areata (AA)

Join Inmagene Biopharmaceuticals for a virtual key opinion leader (KOL) event featuring Emma Guttman, MD, PhD (Icahn School of Medicine…
TIME: 11:00 AM EDT
LOCATION: Virtual
View Details